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Abstract
Draculin, a glycoprotein isolated from vampire bat (Desmodus rotundus) saliva, is a natural anticoagulant which inhibits
activated coagulation factors IX (IXa) and X (Xa). The observation that under captivity conditions, the anticoagulant
activity present in vampire bat saliva is dependent upon the salivation protocol, led us to investigate the possible relationship
between the expression of biological activity of native draculin and the post-translational glycosylation of the protein
backbone. Daily salivation of vampire bats yields a saliva that progressively decreases in anticoagulant activity, without any
significant change in overall protein content, or in the amount of protein specifically recognized by a polyclonal anti-draculin
antibody. Anticoagulant activity of the saliva is restored after a 4-day period of rest. Besides the marked difference in
anticoagulant activity, purified native draculin, obtained from high- and low-activity saliva, shows significant differences in:
(a) composition of the carbohydrate moiety, and (b) Glycosylation pattern. Furthermore, controlled chemical
deglycosylation of native draculin, under conditions that do not affect the polypeptide backbone, progressively leads to
complete loss of the biological activity. Our present results implicate that correct glycosylation of draculin is a seminal event
for the expression of the biological activity of this glycoprotein. ß 1998 Elsevier Science B.V. All rights reserved.
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1. Introduction
Draculin, which is a selective inhibitor of the bio-
logical activity of activated coagulation factors IX
(FIXa) and X (FXa), was ¢rst reported by Apitz-
Castro et al. as a glycoprotein of 88.5 kDa obtained
from saliva of vampire bat Desmodus rotundus [1].
This natural anticoagulant displays a microheteroge-
neous band pattern in SDS^PAGE, commonly found
in most glycoproteins [2]. Since the initial isolation of
draculin, it was observed that the anti-FXa biologi-
0304-4165 / 98 / $ ^ see front matter ß 1998 Elsevier Science B.V. All rights reserved.
PII: S 0 3 0 4 - 4 1 6 5 ( 9 8 ) 0 0 0 8 2 - 8
Abbreviations: FIXa, activated factor IX; FXa, activated fac-
tor X; TFA, tri£uoroacetic acid; TFMS, tri£uoromethanesul-
fonic acid; FACE, £uorophore-assisted carbohydrate electropho-
resis ; SDS^PAGE, sodium dodecyl sulfate^polyacrylamide gel
electrophoresis ; ELISA, enzyme-linked immunosorbent assay;
TMS, trimethylsilyl ; GC^MS, gas chromatography^mass spec-
trometry analysis ; 2-AB, 2-aminobenzamide; GalNAc, N-acetyl-
galactosamine; GlcNAc, N-acetylglucosamine; Man, mannose;
Gal, galactose; AD, active draculin; ID, inactive draculin;
PNA, peanut agglutinin; WGA, wheat germ agglutinin
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cal activity of native draculin is not similar for all
batches, even when saliva is obtained from the same
animals. Among possible explanations to this fact
one can invoke: (a) diminished production of the
native protein, or (b) Impairment of relevant post-
translational modi¢cations of the protein, both due
to environmental changes that vampire bats undergo
when kept in captivity.
It is now well established that the appropriate gly-
cosylation of proteins may be relevant to the expres-
sion of their biological activity and that the set of
glycoforms of a given polypeptide expressed by an
organism is dependent on its physiological state [3,4].
In this paper, we report results that indicate that the
anticoagulant activity of draculin is highly dependent
on the proper glycosylation of the polypeptide back-
bone.
2. Materials and methods
2.1. Materials and reagents
Hydroxyapatite (Biogel-HTP), acrylamyde and sil-
ver staining reagents were purchased from Bio-Rad
(Richmond, CA, USA). Coagulation factors were
kindly provided by Dr. Rob Wagenvoord (Depart-
ment of Biochemistry, University of Limburg, Neth-
erlands). The activity of FXa was measured using the
chromogenic substrates S2222 (Km=200 WM, Chro-
mogenix, Sweden) and S2337 (Km=200 WM, Kabi
Diagnostica, Sweden). For continuous measurement
of thrombin generation we used the substrate SQ68.
The following reagents were purchased from Oxford
GlycoSystems (USA): GlycoFree deglycosylation kit,
GlycoRelease kit, Signal 2-AB kit and HPLC Glyco-
Sep. For the electrophoresis of the £uorophore-la-
beled carbohydrates we used the FACE N-linked oli-
gosaccharide pro¢ling system provided by Glyco
(CA, USA). Neuraminidase X type (EC 3.2.1.18)
was a gift from Dr. Raimundo Villegas (IDEA, Bar-
uta, Venezuela). Freund's complete adjuvant (FCA)
was from Calbiochem (CA, USA) and Freund's in-
complete adjuvant (FIA) was from Gibco (OH,
USA). EGGstract puri¢cation system and Anti-
chicken IgY AP conjugate were supplied by Promega
(WI, USA). WGA and PNA lectins were provided by
Vector (CA, USA). All other reagents used were of
the highest quality commercially available. For
graphics and mathematical approaches, Origin 5.0
Software was used (Microcal Software, MA, USA).
2.2. Animals
Vampire bats (Desmodus rotundus) were regularly
captured from wild colonies in the region of Choron|̈
(State of Aragua, Venezuela). The bats were kept in
captivity, in individual, metabolic-type cages (Acme
Metal Products, Chicago, IL, USA), under con-
trolled light and temperature (25³C). The animals
were maintained on bovine blood anticoagulated
with 3.8% sodium citrate at a ratio of 1:9. Food
was given every 24 h and water was given ad libitum
[5].
2.3. Saliva collection
For saliva collection, animals were anaesthetized
with a mixture of 2.5% 2-bromo-2-chloro, 1,1,1-tri-
£uorethane (Halothan, Hoechst) and 30% nitrous
oxide in oxygen [5,6]. Once anesthetized, 20 Wl of
1% pilocarpine (Isopto Carpin, Alcon, Ft. Worth,
TX, USA) was placed in the mouth in order to stim-
ulate salivation. Saliva was collected in 2-ml micro-
centrifuge tubes and stored at 320³C until use. Each
sample was assayed for protein concentration and
FXa inhibitory activity, and similar batches were
kept separate and eventually pooled for draculin pu-
ri¢cation.
2.4. Draculin puri¢cation
Draculin was puri¢ed with a modi¢cation of the
original method [1]. Brie£y, the saliva was thawed
and dialyzed for 14 h against distilled water at 4³C.
The dialysate, 1/3 diluted, was adjusted to 1 mM
NaCl and loaded onto a hydroxyapatite column
equilibrated with NaCl at a £ow rate of 0.3 ml/
min. The column was washed with 5 column volumes
of 1 mM NaCl (pH 6.8), followed by 4 column vol-
umes of 200 mM potassium phosphate bu¡er (pH
6.8). After column washing, the elution was initiated
using a phosphate bu¡er gradient from 200 mM (pH
6.8) to 1 M (pH 7.4), and 1-ml fractions were col-
lected at a £ow rate of 0.3 ml/min. Anti-FXa activity
of each fraction was assayed using a microplate
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adaptation of the FXa assay [1]. Fractions with the
best anti-Xa activity were pooled and adjusted to
20% glycerol. An aliquot was taken for protein de-
termination and SDS^PAGE, and the remainder
were aliquoted and kept frozen at 320³C until use.
Presence of draculin with very low inhibitory activity
was established by an ELISA method using a poly-
clonal anti-draculin antibody obtained from egg
yolks.
2.5. Factor Xa activity
Factor Xa activity was assayed on speci¢c chro-
mogenic substrates. For the microplate assay of the
FXa activity, 50 Wl of each of the hydroxyapatite
column-eluted fractions was placed in a well with
100 Wl of bu¡er A (0.05 M Tris^HCl, 0.1 M NaCl
(pH 7.35), with 0.05% egg albumin), 3 nM FXa and
20 Wl of 4 mM S-2222, in a ¢nal volume of 180 Wl.
After 15 min incubation at 37³C the optical density
at 405 nm was recorded in a microplate reader
(EL312e Bio-Kinetics reader microplate, Bio-Tek In-
struments). The continuous assay of FXa activity
was used for quantifying the anti-Xa activity of dra-
culin. Brie£y, 10^13 nmol of FXa was incubated with
draculin for 1 min at 37³C in a cuvette containing
bu¡er A. The cuvette was placed in a home-made
¢xed dual-wavelength photometer (Biochemistry
and Instrumental Department, University of Lim-
burg, Netherlands) for the continuous recording of
the reaction at 405 nm. The reaction was started with
addition of 35 Wl of S-2337 (Final concentration =
400 WM). The ¢nal volume of the reaction mix was
500 Wl.
2.6. Glycosyl composition analysis
This analysis was carried out in the Complex Car-
bohydrate Research Center (Georgia, USA, NIH
Grant no. 2-P41-RR05351-06). Draculin samples
(200 Wg) were analyzed for monosaccharide compo-
sition by preparing the trimethylsilyl (TMS) deriva-
tives of the methyl glycosides followed by gas chro-
matography and combined GC^MS analysis. TMS
methyl glycosides were prepared from the sample
by methanolysis in 3 M HCl in methanol, followed
by N-acetylation with pyridine and acetic anhydride.
These procedures were accomplished as previously
described [7]. GC analysis of the TMS methyl glyco-
sides was done on an HP 5890 GC using a Supelco
DB1 fused silica capillary column. GC/MS analysis
was performed using a Hewlett Packard 5890 GC
coupled to a 59790 MSD.
2.7. Treatment of draculin with neuraminidase
In order to probe the e¡ect of sialic acid re-
motion in the inhibitory activity of draculin, native
draculin was treated with neuraminidase (EC
3.2.1.18), 0.1 U/ml ¢nal concentration at room tem-
perature; aliquots were taken at the indicated times
and assayed for its residual anti-FXa activity.
2.8. Chemical deglycosylation of native draculin
Draculin was deglycosylated by a chemical proce-
dure [8]. Brie£y, draculin (100 Wg) was extensively
dialyzed against 0.1% tri£uoroacetic acid (TFA) at
4³C and freeze-dried for s 48 h. Draculin was mixed
with 50 Wl tri£uoromethanosulfonic acid (TFMS)
and the mixture was placed in a freezer at 320³C
for 4^12 h. Excess of TFMS was neutralized using
60% pyridine and then 0.5% ammonium bicarbonate.
The polypeptide backbone was recovered by centri-
fugation/ultra¢ltration, subjected to SDS^PAGE and
assayed for its inhibitory activity against FXa as de-
scribed.
2.9. N-Linked oligosaccharides pro¢le of draculin
(FACE)
The N-linked oligosaccharides from active and in-
active draculin were compared by £uorophore-assist-
ed carbohydrate electrophoresis (FACE) [9], follow-
ing the procedure recommended by the manufacturer
(Glyco, CA, USA). Brie£y, the oligosaccharides from
draculin were released by peptide N-glycosidase F
(EC 3.5.1.52) and the released oligosaccharides
were then labeled with a £uorophore (8-aminonafta-
len-1,3,6-trisulfonate) at the reducing termini by re-
ductive amination. The £uorescent labeled oligosac-
charides were separated by PAGE. Imaging of the
gel was performed on a UV light box and then pho-
tographed for further analysis. The resulting banding
pattern represents the N-linked oligosaccharide pro-
¢le of the glycoprotein.
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2.10. Chemical cleavage and isolation of N- and
O-linked oligosaccharides from draculin
The hydrazinolysis procedure [10] was used for the
obtainment of intact N- and O-linked oligosacchar-
ides from draculin. Draculin (active and inactive)
was exhaustively dialyzed against 0.1% TFA and
then dried thoroughly by lyophilization. The dried
sample was mixed with hydrazine and placed for
5 h at 95³C in a heating block. The reaction mixture
was transferred to a column for chromatographic
removal of unreacted hydrazine and peptide material
from glycans. The N-acetyl groups cleaved during
hydrazinolysis are re-N-acetylated using a solution
of acetic anhydride and unreduced by the addition
of Cu2 ions. The glycans were ¢nally recovered us-
ing a ion-exchange column. One portion of the N-
and O-released oligosaccharides was saved for assay-
ing inhibitory activity both on FXa and on thrombin
generation in human blood plasma, and the remain-
ing was labeled with 2-aminobenzamide (2-AB) by
reductive amination using Signal 2-AB Labeling Kit
(Oxford GlycoSystem, USA).
2.11. HPLC of labeled oligosaccharides from draculin
2-AB-labeled oligosaccharides from active and in-
active draculin were separated by HPLC using a
DEAE anionic-exchange column (GlycoSep C) and
a hydrophobic column (GlycoSep H), both columns
from Oxford GlycoSystems. The detection was per-
formed at 330 nm.
2.12. Other methods
Protein determination was done by the Bradford
method [11]. SDS^PAGE was done as described by
Schagger and von Jagow [12]. Gels were stained with
Coomassie blue or silver staining. The procedure for
the obtention of polyclonal anti-draculin antibodies
from egg yolk was as previously described [13].
Brie£y, two hens were inoculated subcutaneously
with 50 Wg of draculin (active and inactive) in FCA
and booster injections (50 Wg of draculin in FIA)
were applied at 7, 21, 30, 60 days and then at
2 months interval. The eggs were collected and stored
at 4³C. IgY was obtained using the Promega puri¢-
cation system; both IgY antibodies were equally able
to recognize active and inactive draculin. For West-
ern-blotting analysis, appropriate methods were used
[14,15]. The e¡ect of the intact oligosaccharides on
thrombin generation in human blood plasma was
assayed as described [16]. Brie£y, 400 Wl of de¢bri-
nated plasma and 100 Wl of bu¡er A, to which oli-
gosaccharides were added, were incubated with Ac-
tin-FS (37³C, 3 min). The reaction was started by
adding 40 Wl of 7.5 mM chromogenic substrate SQ-
68 and 20 Wl of 0.5 M CaCl2, and the optical density
at 405 nm was recorded. The e¡ect of adding an
excess of a mixture of inactive draculin and the iso-
lated oligosaccharides was also measured in both the
puri¢ed F Xa system and in plasma, as described
before.
The e¡ect of preincubation of draculin with wheat
germ agglutinin (WGA) and peanut agglutinin
(PNA) lectins on the anti-Xa activity was assayed
as follows: draculin (0.18 Wg) and the respective lec-
tin (0.1 mg) were incubated for 10 min at 37³C; the
chromogenic substrate S2337 was added and the re-
action was started with the addition of FXa (0.8 nM).
Recording of the FXa activity was as described
above. Preincubation of these lectins with FXa did
not have e¡ect on the amydolytic activity of FXa.
3. Results
3.1. Dependence of the anticoagulant activity on
salivation frequency
Fig. 1A shows the results of anti-Xa activity and
protein concentration of saliva obtained from three
groups of ¢ve animals daily salivated for 5 days and
after a rest of 3 days. As shown in Fig. 1A, daily
salivation of vampire bats results in production of
saliva with decreasing anti-Xa activity, reaching val-
ues around 45% of day 1 after 5 days of daily sali-
vation; however, overall protein concentration dur-
ing the same period, does not change signi¢cantly.
Although our present results were obtained after
5 days of continuous salivation, it should be noted
that the same trend is observed after up to 8 days of
daily salivation, when the anti-Xa activity decreased
to about 30% of the original (two animals). Fig. 1A
also shows the recovery of anti-Xa activity to the
values of day 1 after a 3-day period of rest. Further-
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more (Fig. 1B), Western blotting analysis of the sal-
iva, using a polyclonal anti-draculin antibody, shows
that the amount of protein speci¢cally recognized by
the antibody is essentially identical from day 1 to day
5, in contrast with the marked decrease in antico-
agulant activity. Draculin, puri¢ed from separated
pools of samples of `high-' and `low-activity' salivas,
as previously described [1], was arbitrarily designed
as `active' or `inactive' draculin. Active draculin
(AD) inhibited FXa at molar ratios draculin:FXa
below 4, whereas inactive draculin (ID) needed molar
ratios higher than 10 to achieve s 90% inhibition,
under identical experimental conditions. Draculin
with extremely low anticoagulant activity was de-
tected by an ELISA procedure, as described in Sec-
tion 2.
3.2. Glycosyl composition of active and inactive
draculin
Carbohydrate composition of AD and ID is
shown in Table 1. The major monosaccharides iden-
ti¢ed in both proteins (sialic acid, GlcNAc, Man and
Gal) indicate the presence of N-linked oligosacchar-
Fig. 1. (A) Speci¢c anti-Xa activity (white columns) and protein concentration (dashed columns) of saliva obtained daily. Days 6, 7
and 8 correspond to salivation rest. Speci¢c anti-FXa activity and protein concentration values are the mean þ S.E. of saliva obtained
from three groups of ¢ve animals each. (B) Typical Western blot pattern of salivas from days 1 to 5 and after rest period shown in
A. Marks at right show the position of the 94 kDa and 67 kDa markers.
Table 1
Glycosyl composition of active and inactive draculin
Glycosyl residue Active draculin Inactive draculin
Percent of total
carbohydrate
Percent (w/w) of total
protein
Percent of total
carbohydrate
Percent (w/w) of total
protein
Sialic acid 32.3 22.3 22.2 2.6
GlcNAc 23.6 16.3 11.8 1.4
Mannose 18.1 12.5 34.4 4.0
Galactose 15.1 10.4 14.9 1.7
GalNAc 5.8 4.0 4.5 0.5
Glucose 3 2.1 8.6 1.0
Fucose 0.8 0.6 3.6 0.4
Glucuronic acid 0.8 0.6 n.d. n.d.
Xylose 0.7 0.5 n.d. n.d.
Carbohydrate/protein (% w/w): active draculin 69%, inactive draculin 11.5%. n.d., not detected.
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ides, although the presence of GalNAc suggests also
the existence of O-linked oligosaccharides. Data in
Table 1 show signi¢cant di¡erences in carbohydrate
composition between AD and ID, both quantitative
and qualitative. While AD has about 69% (w/w) car-
bohydrate content, in ID it only reached 11%. Major
qualitative di¡erences are found in the relative
amount of sialic acid, mannose, GlcNAc and glu-
cose.
3.3. E¡ect of neuraminidase treatment in anti-FXa
activity of draculin
Neuraminidase treatment of native, active draculin
results only in 10% to 15% loss of anticoagulant
activity, compared to the untreated sample, even
after 24 h incubation (Fig. 2). The ¢gure also shows
that untreated draculin (control) progressively losses
activity, reaching about 80% of the original after 24 h
at 25³C.
3.4. Glycosyl pro¢le analysis of active and inactive
draculin
The electrophoretic pro¢le of enzymatically re-
leased oligosaccharides from AD and ID obtained
by FACE is shown in Fig. 3. Internal standard con-
sisting in a mixture of glucose polymers ranging from
glucose 3 to glucose 11 was run simultaneously. As
shown in the ¢gure, marked di¡erences are found in
the oligosaccharide pro¢les of AD and ID. AD
clearly displays a higher content of larger oligosac-
charide chains than the inactive counterpart.
Additionally, chemically released oligosaccharides
from AD and ID were chromophore-labeled and
separated by HPLC. The anionic HPLC pro¢le of
chemically released oligosaccharides from AD and
ID is shown in Fig. 4. Major di¡erences in the
elution pattern are observed in the area of neutral
(W5 min) and monosialylated structures (10^15 min),
where peaks corresponding to inactive draculin are
clearly more prominent. Di- and trisialylated struc-
tures are more abundant in active draculin, as can be
seen from the peaks eluting at 20^25 and at 45 min,
respectively. Di¡erences can be observed also at
higher elution times, where more complex structures
appear. Hydrophobic-HPLC also shows marked dif-
ferences in the elution pattern. They are especially
important in the initial peaks, corresponding to
charged structures, which are more prominent in ac-
tive draculin (not shown).
3.5. E¡ect of controlled chemical deglycosylation on
draculin activity
Active draculin, when subjected to chemical degly-
cosylation under conditions where the primary struc-
ture of the protein backbone is completely preserved
as demonstrated by Sojar and Bahl [8], lose activity
in a manner dependent on the degree of deglycosy-
lation. Table 2 shows the e¡ect of deglycosylation
time of draculin on its inhibitory activity. The FXa
inhibitory e¡ect of draculin (4.0 Wg/ml) decreased by
Fig. 3. FACE of enzymatically released N-oligosaccharides
from active and inactive draculin. Arrows correspond to the po-
sition of the glucose ladder used as internal standard.
Fig. 2. Time course of anti-Xa activity of draculin treated with
Neuraminidase. Native draculin incubated at 25³C with bu¡er
A was used as control.
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39% after 4 h deglycosylation, while it was com-
pletely lost after 12 h deglycosylation. The e¡ect of
deglycosylation on the mobility of draculin in SDS^
PAGE is seen in Fig. 5. The sharp band obtained
after 12 h deglycosylation treatment corresponds to
a polypeptide chain of about 72 kDa molecular
mass, and there is no di¡erence between deglycosy-
lated ID and AD (not shown). Furthermore, no low-
er molecular mass polypeptide was observed, indicat-
ing the integrity of the polypeptide chain. This is in
good agreement with the molecular mass of the pro-
tein calculated from the amino acid composition of
native draculin [1]. On the other hand, deglycosy-
lated draculin is recognized by the polyclonal anti-
draculin antibody, showing that the polypeptide
chain still conserves some identical immunologic
epitopes.
3.6. E¡ect of released oligosaccharides from native
draculin on Thrombin generation in whole human
plasma
Intact oligosaccharides obtained after hydrazino-
lysis of native AD were assayed for inhibitory activity
on thrombin generation in human blood plasma, as
described in Section 2. Even at concentrations far in
excess of the concentrations of native draculin
needed for complete inhibition of thrombin genera-
tion, addition of isolated oligosaccharides did not
elicit any detectable change in the generation of
thrombin. Also, adding intact oligosaccharides to in-
active draculin did not restore its anti-F Xa activity
(not shown). Similarly, incubation of plasma with the
deglycosilated polypeptide backbone of draculin did
not a¡ect thrombin generation.
3.7. E¡ect of lectins on the anti-Xa activity of
draculin
Fig. 6 shows the e¡ect of WGA and PNA lectins
on the anti-Xa activity of draculin. As can be seen,
preincubation of draculin with WGA completely
abolished the inhibitory activity of draculin on
FXa, while PNA preincubation has a moderate e¡ect
on anti-FXa activity of draculin.
4. Discussion
The results reported above show that oligosacchar-
ides linked to draculin are essential for the optimal
expression of its biological activity against FXa.
Fig. 5. SDS^PAGE of native and deglycosylated draculin. Ap-
proximate molecular masses are shown. Lane A, native dracu-
lin; lane B, N-endoglycosidase-treated draculin; lane C, chemi-
cally deglycosylated draculin (4 h); lane D, chemically
deglycosylated draculin (12 h). Experimental conditions for
N-endoglycosidase treatment (SDS 0.1%, 2-mercaptoethanol
50 mM, Nonidet P-40 0.75%) impairs assay of anti-Xa activity.
Fig. 4. DEAE^HPLC pro¢le of labeled N- and O-oligosacchar-
ides from active and inactive draculin. Carbohydrate chains
were released by hydrazinolysis and labeled with 2-AB as de-
scribed in Section 2.
Table 2
E¡ect of controlled chemical deglycosylation on anti-FXa activ-
ity by draculin
Draculin (Wg/ml) Deglycosylation time
0 h 4 h 12 h
2 39.1 28 0
3.2 50 38.4 0
4 93.8 57.3 0
6.3 s 95 n.d. 0
12.7 s 95 n.d. 11.2
19.1 s 95 s 95 12.2
n.d., Not determined.
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They also suggest that native draculin is secreted as
a mixture of glycoforms, whose ¢nal anticoagulant
activity depends upon the relative proportion of cor-
rectly glycosylated molecules to partially or improp-
erly glycosylated ones. Hence, it seems that glycosy-
lation and not protein synthesis is the limiting step
for production of native draculin with optimal anti-
coagulant activity. Although it is possible that chem-
ical deglycosilation, even under the mild conditions
used, may cause protein denaturation, the fact that
native draculin and chemically deglycosylated dracu-
lin are similarly recognized by the anti-draculin anti-
body suggest that chemical denaturation is not the
main cause of the loss of the biological activity. At
present, however, it is not clear if not only the
amount of carbohydrates, but also the structure of
the oligosaccharides plays a relevant role in the ex-
pression of the activity. Although it has been de-
scribed that desialidation notably impairs the func-
tion of various glycoproteins [17,18], data in Fig. 2
suggest that sialic acid residues probably play a mi-
nor role in the biological activity of draculin. Evi-
dence for the recognition of oligosaccharides linked
to protein as signi¢cant part in the establishment of
the biological activity of glycoprotein have increased
in the last two decades. They have been implicated in
a variety of functions such as structural role, in the
conformation and stability of proteins, as target for
immune response and microorganism attack, and in
the mediation of cell^matrix and cell^cell interactions
[19]. At the molecular level, it might be advantageous
that the biological activity of draculin be dependent
on the correctness of the carbohydrate moiety rather
than in the protein backbone, in contrast with the
case presented by Klaassen et al., who found that the
acquisition of N-linked oligosaccharide moieties, and
not their structures, was essential for biosynthesis of
functional gastric H,K-ATPase in insect cells [20].
In this regard, the appropriate glycosylation of dra-
culin may be in part responsible for the dual, inde-
pendent, inhibitory action of native draculin on
FIXa and FXa, suggesting a novel mechanism of
inhibition which is di¡erent from other known natu-
ral inhibitors of FXa [21^23]. The inhibition of the
anti-Xa activity of draculin, after incubation with the
lectins WGA and PNA, gives further support to the
role of the oligosaccharide chains in the expression of
the anticoagulant activity. The fact that intact oligo-
saccharides, obtained from chemical cleavage of na-
tive draculin, do not inhibit FXa in arti¢cial systems
or in human plasma shows that these oligosacchar-
ides, unlike the anticoagulant polysaccharide hepa-
rin, do not act by boosting the anticoagulant activity
of a plasma serpin like antithrombin. Because the
admixture of the isolated oligosaccharides from dra-
culin to inactive draculin did not restore the inhibi-
tory activity, it appears that, unlike in the heparin^
antithrombin interaction, covalent linkage is a pre-
requisite for biological activity. The ensemble of
these results suggests that their role in the native
protein may be related to the maintenance of a con-
formational state that recognizes and binds to certain
speci¢c domains in both Factor IXa and Xa. Since
FXa has a key role in the coagulation system and its
inhibition has been shown to be an important point
for anticoagulant therapy, our present e¡orts have
been focused to the study of anti-Xa activity of dra-
culin; however, the fact that deglycosilated draculin
did not a¡ect thrombin generation in plasma suggest
that inhibition of activated Factor IX is also depend-
ent on draculin glycosylation.
The presence of di¡erent oligosaccharide struc-
tures in the same glycoprotein results in a subset of
glycoforms that have di¡erent physical and biochem-
ical properties which may in£uence the glycoprotein
functionality [4]. A variety of reports shows that the
extracellular environment, e.g., pregnancy and acute
Fig. 6. E¡ect of incubation of native draculin with the lectins
WGA and PNA on anti-FXa activity. The progressive curves
of the activity of FXa on S2337 are shown. Control, FXa activ-
ity; DRAC, anti-FXa activity of draculin; +WGA, draculin
preincubated with WGA; +PNA, draculin preincubated with
PNA.
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in£ammation, may a¡ect glycosylation of certain
polypeptides [24]. Lifely et al. reported di¡erences
in the glycosylation pattern and the biological activ-
ity of CAMPATH-1H, a humanized IgG antibody
used in the therapy of lymphoma, leukemia and
rheumatoid arthritis, when it was expressed in di¡er-
ent cell lines and grown under variable culture con-
ditions [25]. The fact that draculin with poor inhib-
itory activity was obtained from batches of saliva
after consecutive salivation days, which imposes a
metabolic stress, in addition to the captivity condi-
tions, implicates metabolic as well as environmental
factors in the di¡erent glycosylation pattern observed
in inactive draculin. Although there was no di¡er-
ence in the SDS^PAGE mobility between deglycosy-
lated ID and AD, some minor, not easily detected
polymorphism in the polypeptide sequence cannot be
discarded, as shown in corticosteroid-binding globu-
lin by Ali and Bassett [26]. At the moment, we do
not have direct evidence of such polymorphism be-
tween ID and AD.
To summarize, draculin as a glycoprotein requires
a particular glycosylation pro¢le for expression of its
maximal inhibitory activity, a fact that should be
taken into consideration for further studies concern-
ing cloning of the protein or the obtainment of gly-
copeptides biologically active against FXa, a poten-
tial strategy for the design of new anticoagulants.
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